ArticleACS omega2026
Characterization of Thermoresponsive Methylcellulose-Based Injectable Hydrogels Incorporating 58S Bioactive Glass for Non-Load-Bearing Bone Regeneration.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone fractures represent a significant global public health challenge, particularly in aging populations. Despite extensive research, injectable systems that balance bioactivity with precise handling properties remain scarce. In this study, a novel triple-polymeric blend of methylcellulose, xanthan gum, and pullulan was developed using design of experiments (DoE) to create a multifunctional bioactive carrier for 58S Bioglass. This synergistic matrix was designed for minimally invasive application in non-load-bearing bone regeneration. A comprehensive physicochemical and rheological characterization was performed, as well as preliminary biological screening. The formulations were evaluated for rheological behavior, injectability, mechanical properties, swelling, degradation, thermal stability, morphology, and cytotoxicity. The innovative blend achieved precise gelation near physiological temperatures and high postinjection stability, with viscosity recovery exceeding 80% and pseudoplastic behavior tailored for injectable delivery. Low compressive moduli (∼0.01 kPa) confirmed an ultrasoft nature, prioritizing its role as a localized signaling vehicle over structural support. Degradation studies showed that increasing bioactive glass content modulates mass loss through ionic interactions within the polymeric network. Preliminary biological assays demonstrated no cytotoxicity against L929 mouse fibroblasts and human dental pulp mesenchymal stem cells (DPSCs). Morphological analysis revealed porous, interconnected structures influenced by the bioglass content. Overall, this study establishes the feasibility of a novel hydrogel designed as a versatile and smart platform for minimally invasive bioactive glass delivery in non-load-bearing bone tissue repair.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.